{
  "name": "Kymera Therapeutics",
  "ticker": "KYMR",
  "headquarters": "Watertown, MA",
  "website": "www.kymeratx.com",
  "description": "Industry leader in developing oral degrader medicines with a focus on immunology. Building an industry leading pipeline of oral medicines with biologics-like activity to transform treatments for patients with immunological diseases.",
  "modalities": [
    "Oral small molecule degraders"
  ],
  "therapeutic_focus": [
    "Immunology",
    "Oncology"
  ],
  "cash_runway": "Into 2029",
  "partnerships": [
    {
      "partner": "Sanofi",
      "asset": "KT-485 (IRAK4 degrader)",
      "deal_value": null,
      "status": "Active",
      "source_page": 51
    },
    {
      "partner": "Gilead",
      "asset": "CDK2 molecular glue degraders",
      "deal_value": "Up to $750 million in total payments, including $85 million in upfront and potential option exercise payments",
      "status": "Active",
      "source_page": 52
    }
  ],
  "investment_thesis": [
    "Unrivaled science and expertise: Innovative, experienced team and capabilities to develop revolutionary oral therapies to transform the treatment of immunological diseases",
    "Patient-first mentality, with urgency: Rapidly advancing first-in-industry oral degraders with biologics-like activity",
    "Defining and surpassing clinical benchmarks: Demonstrated compelling clinical translation of degraders' impact on clinical endpoints",
    "Scaling for the future: Building a fully integrated global company to deliver a new class of immunology medicines",
    "Oral degraders that combine the activity of injectable biologics with the convenience of oral drugs have the potential to transform current treatment paradigms",
    "Over 140M patients diagnosed with immunological diseases with only ~5M (3%) having access to advanced therapies, representing >$100B in annual sales opportunity"
  ],
  "key_risks": [
    "Risk that the results of prior preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical studies and clinical trials",
    "Risk that cross-trial comparisons may not be reliable as no head-to-head trials have been conducted comparing KT-621 to dupilumab",
    "Risk that strategic partnerships with Sanofi and Gilead may not be able to successfully accelerate the development and commercialization of programs",
    "Timing and outcome of any interactions with regulatory authorities",
    "Availability of funding sufficient for the Company's operating expenses and capital expenditure requirements"
  ],
  "_source_pages": [
    1,
    3,
    4,
    54
  ],
  "_extracted_at": "2026-02-04T13:13:42.032646",
  "_last_extracted": "2026-02-04T13:13:42.033260"
}